Literature DB >> 27518677

Radiation plus Chemotherapy in Low-Grade Glioma.

Jan C Buckner, Arnab Chakravarti, Walter J Curran.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27518677     DOI： 10.1056/NEJMc1605897

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas.

Authors:  Talia C Oughourlian; Jingwen Yao; Jacob Schlossman; Catalina Raymond; Matthew Ji; Hiroyuki Tatekawa; Noriko Salamon; Whitney B Pope; Johannes Czernin; Phioanh L Nghiemphu; Albert Lai; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2020-01-24       Impact factor: 4.130

Review 2.  Guidelines in the management of CNS tumors.

Authors:  Navid Redjal; Andrew S Venteicher; Danielle Dang; Andrew Sloan; Remi A Kessler; Rebecca R Baron; Constantinos G Hadjipanayis; Clark C Chen; Mateo Ziu; Jeffrey J Olson; Brian V Nahed
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

3.  The benefit of early surgery on overall survival in incidental low-grade glioma patients: A multicenter study.

Authors:  Tamara Ius; Sam Ng; Jacob S Young; Barbara Tomasino; Maurizio Polano; David Ben-Israel; John J P Kelly; Miran Skrap; Hugues Duffau; Mitchel S Berger
Journal:  Neuro Oncol       Date:  2022-04-01       Impact factor: 13.029

4.  Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.

Authors:  Jonathan Weller; Sophie Katzendobler; Jens Blobner; Frederic Thiele; Hannes Becker; Stefanie Quach; Rupert Egensperger; Maximilian Niyazi; Bogdana Suchorska; Niklas Thon; Michael Weller; Joerg-Christian Tonn
Journal:  J Neurooncol       Date:  2022-09-16       Impact factor: 4.506

5.  Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib.

Authors:  Benjamin M Ellingson; Grace Hyun J Kim; Matt Brown; Jihey Lee; Noriko Salamon; Lori Steelman; Islam Hassan; Shuchi S Pandya; Saewon Chun; Michael Linetsky; Bryan Yoo; Patrick Y Wen; Ingo K Mellinghoff; Jonathan Goldin; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

6.  The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas.

Authors:  Ricardo Gargini; Berta Segura-Collar; Beatriz Herránz; Vega García-Escudero; Andrés Romero-Bravo; Felipe J Núñez; Daniel García-Pérez; Jacqueline Gutiérrez-Guamán; Angel Ayuso-Sacido; Joan Seoane; Angel Pérez-Núñez; Juan M Sepúlveda-Sánchez; Aurelio Hernández-Laín; María G Castro; Ramón García-Escudero; Jesús Ávila; Pilar Sánchez-Gómez
Journal:  Sci Transl Med       Date:  2020-01-22       Impact factor: 17.956

7.  Establishment and Preliminary Characterization of Three Astrocytic Cells Lines Obtained from Primary Rat Astrocytes by Sub-Cloning.

Authors:  Fabio Caradonna; Gabriella Schiera; Carlo Maria Di Liegro; Vincenzo Vitale; Ilenia Cruciata; Tiziana Ferrara; Pietro D'Oca; Riccardo Mormino; Simona Maria Angela Rizzo; Italia Di Liegro
Journal:  Genes (Basel)       Date:  2020-12-13       Impact factor: 4.096

8.  PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.

Authors:  Jonathan Weller; Sophie Katzendobler; Philipp Karschnia; Stefanie Lietke; Rupert Egensperger; Niklas Thon; Michael Weller; Bogdana Suchorska; Joerg-Christian Tonn
Journal:  J Neurooncol       Date:  2021-05-01       Impact factor: 4.130
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.